Uncategorized

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

Published

on

A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for derisked companies. Plus, FDA decisions slow only slightly as the hunt for a permanent leader drags on.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version